Arca
Skip to content

Merkel cell carcinoma

Drug research and approvals for merkel cell carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 36 studies of merkel cell carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 36
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 36 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jun 24, 2024A randomized phase 2 study of atr inhibition in advanced pd-(l)1-refractory merkel cell carcinoma: the matrix trialTUVUSERTIB (M1774) / AVELUMABUNIVERSITY HEALTH NETWORKOngoing
Nov 9, 2021A phase 1b/2, open-label study evaluating the safety and efficacy ofkrt-232 in patients with p53 wild-type (p53wt) merkel cell carcinoma (mcc) who have failed…NAVTEMADLIN (KRT-232) / AVELUMABKARTOS THERAPEUTICS INCOngoing
Nov 26, 2018A phase 3 open-label, single arm study to evaluate the safety and efficacy of pembrolizumab (mk-3475) as first-line therapy in participants with advanced…KEYTRUDAMerck & Co. (MSD)Ongoing
Oct 17, 2018A phase 2 study of incmga00012 in participants with metastatic merkel cell carcinomaINCMGA00012 (MGA012)Incyte CorporationClosed
May 24, 2017A phase II, open-label, multicenter trial to investigate the clinical activiity and safety of avelumab (msb0010718c) in subjects with merkel cell carcinomaMSB0010718C (AVELUMAB)Merck KGaAClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 22, 2023Zynyztreatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)Incyte CorporationApproved
Dec 19, 2018KeytrudaKEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinomaMSD International Business GmbHApproved
Mar 23, 2017BavencioTreatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinomaEMD Serono Research and Development Institute, Inc.Approved
Mar 21, 2024topotecan liposome injectionTreatment of Merkel Cell CarcinomaFujifilm Pharmaceuticals U.S.A., Inc.Designated
Oct 17, 2022bi-specific fragment crystallizable region (Fc) fusion…Treatment of Merkel cell carcinomaGI Innovation, Inc.Designated
Mar 1, 2021cavrotolimodTreatment of merkel cell carcinomaExicure, Inc.Designated
Apr 8, 2020navtemadlinTreatment of Merkel cell carcinomaKartos Therapeutics, Inc.Designated
Mar 15, 2017activated natural killer[aNK])Treatment of Merkel cell carcinomaImmunityBio, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 18, 2017BavencioavelumabMerck Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.